NO20041681L - Substituerte 4-fenyl-4-[1H-imidazol-2-yl]-piperidinderivater for reduksjon av iskemisk skade - Google Patents

Substituerte 4-fenyl-4-[1H-imidazol-2-yl]-piperidinderivater for reduksjon av iskemisk skade

Info

Publication number
NO20041681L
NO20041681L NO20041681A NO20041681A NO20041681L NO 20041681 L NO20041681 L NO 20041681L NO 20041681 A NO20041681 A NO 20041681A NO 20041681 A NO20041681 A NO 20041681A NO 20041681 L NO20041681 L NO 20041681L
Authority
NO
Norway
Prior art keywords
imidazol
phenyl
substituted
ischemic damage
agent
Prior art date
Application number
NO20041681A
Other languages
English (en)
Inventor
Marcel Jan Maria Borgers
Frans Eduard Janssens
Joseph Elisabeth Leenaerts
Francisco Javi Fernandez-Gadea
Theo Frans Meerts
Antonio Gomez-Sanchez
Willem Flameng
Paul Joannes Ludovic Herijgers
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20041681L publication Critical patent/NO20041681L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Den foreliggende oppfinnelse vedrører et middel for å redusere iskemisk skade på et organ, spesielt et hjerte og en hjerne, farmasøytiske sammensetninger omfattende midlet og anvendelsen av midlet for behandlingen av iskemiske sykdommer på hjertet og hjernen. Midlet omfatter et substituert 4-fenyl-4-[IH-imidazol-2-yl]-piperidinderivat ifølge formel (1). Anvendelsen av midlene har viktige kliniske forgreninger med hensyn på reduksjonen av iskemisk skade på et organ i et pattedyr, spesielt et hjerte og/eller en hjerne, forebyggingen av koronararteriesykdommer i et pattedyr ved å indusere en kardiobeskyttende effekt og behandlingen og forebyggingen av slag.
NO20041681A 2001-10-15 2004-04-23 Substituerte 4-fenyl-4-[1H-imidazol-2-yl]-piperidinderivater for reduksjon av iskemisk skade NO20041681L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01203927 2001-10-15
PCT/EP2002/011371 WO2003039440A2 (en) 2001-10-15 2002-10-10 Substituted 4-phenyl-4-(1h-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage

Publications (1)

Publication Number Publication Date
NO20041681L true NO20041681L (no) 2004-04-23

Family

ID=8181081

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041681A NO20041681L (no) 2001-10-15 2004-04-23 Substituerte 4-fenyl-4-[1H-imidazol-2-yl]-piperidinderivater for reduksjon av iskemisk skade

Country Status (26)

Country Link
US (1) US7390822B2 (no)
EP (1) EP1438049B1 (no)
JP (1) JP4418676B2 (no)
KR (1) KR100967599B1 (no)
CN (1) CN1283252C (no)
AR (1) AR036800A1 (no)
AT (1) ATE345799T1 (no)
AU (1) AU2002363369B2 (no)
BR (1) BR0213325A (no)
CA (1) CA2462374C (no)
CY (1) CY1106335T1 (no)
DE (1) DE60216310T2 (no)
EA (1) EA007657B1 (no)
ES (1) ES2276980T3 (no)
HR (1) HRP20040325A2 (no)
HU (1) HUP0402332A3 (no)
IL (1) IL161347A0 (no)
MX (1) MXPA04003480A (no)
MY (1) MY139586A (no)
NO (1) NO20041681L (no)
NZ (1) NZ531733A (no)
PL (1) PL370371A1 (no)
PT (1) PT1438049E (no)
UA (1) UA75980C2 (no)
WO (1) WO2003039440A2 (no)
ZA (1) ZA200402816B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
CL2004000754A1 (es) * 2003-04-11 2005-02-25 Janssen Pharmaceutica Nv Uso de compuestos derivados de 4-fenil-4-(1h-imidazol-2-il)piperidina, como agonistas delta-opioides no peptidicos, para preparar un medicamento util en prevenir o tratar trastornos del sistema nervioso central.
WO2005005478A2 (en) * 2003-07-02 2005-01-20 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled opioid receptor; delta 1 (oprd1)
WO2005015242A1 (en) * 2003-08-06 2005-02-17 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled opioid receptor kappa 1 (opkr1)
TW200633990A (en) * 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
CN101932577B (zh) 2007-11-30 2013-07-17 拜耳知识产权有限责任公司 杂芳基取代的哌啶
DE102009014484A1 (de) 2009-03-23 2010-09-30 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022896A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022894A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009056387B9 (de) * 2009-10-30 2020-05-07 Osram Opto Semiconductors Gmbh Kantenemittierender Halbleiterlaser mit einem Phasenstrukturbereich zur Selektion lateraler Lasermoden
HUE070649T2 (hu) 2017-10-19 2025-06-28 Teijin Pharma Ltd Benzimidazol-származékok és felhasználásuk
CN113209294B (zh) * 2020-02-05 2023-06-13 复旦大学 Dor激动剂在制备对抗肾脏纤维化药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2244968T3 (es) 1995-03-06 2005-12-16 Interneuron Pharmaceuticals Incorporated Reduccion del volumen de infarto usando citocolina.
EP1283268A3 (en) 1996-08-23 2004-01-02 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor D (VEGF-D)
CN1260835A (zh) 1997-04-25 2000-07-19 科莱特诺医疗公司 截短的vegf相关蛋白质
US6103722A (en) * 1997-07-23 2000-08-15 The Medical College Of Wisconsin Research Foundation Inc. Ischemic preconditioning
GB2332373A (en) * 1997-12-19 1999-06-23 Merck & Co Inc Treatment of coronary and/or peripheral ischemia using an antithrombotic agent and an angiogenesis promoter
EE04917B1 (et) * 1998-12-19 2007-10-15 Janssen Pharmaceutica N.V. Antihistamiinsed spirohendid, vahehendid ja farmatseutiline kompositsioon ning nende valmistamismeetodid ja kasutamine
EP1038872A1 (en) * 1999-02-22 2000-09-27 Pfizer Products Inc. 4-Phenyl-4-heteroarylpiperdine derivatives as opioid receptor ligands
US6297256B1 (en) * 1999-06-15 2001-10-02 Neurogen Corporation Aryl and heteroaryl substituted pyridino derivatives GABA brain receptor ligands
EA006507B1 (ru) * 2001-10-15 2005-12-29 Янссен Фармацевтика Н.В. Новые замещенные 4-фенил-4-[1h-имидазол-2-ил] пиперидиновые производные и их применение в качестве селективных непептидных агонистов дельта-опиоидов
FR2831166B1 (fr) 2001-10-18 2004-02-27 Sanofi Synthelabo Aralkyl-tetrahydro-pyridines, leur preparation et compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
CN1568186A (zh) 2005-01-19
PL370371A1 (en) 2005-05-16
CN1283252C (zh) 2006-11-08
WO2003039440A2 (en) 2003-05-15
JP4418676B2 (ja) 2010-02-17
PT1438049E (pt) 2007-02-28
CA2462374A1 (en) 2003-05-15
CY1106335T1 (el) 2011-10-12
BR0213325A (pt) 2004-10-13
CA2462374C (en) 2011-01-18
AR036800A1 (es) 2004-10-06
DE60216310T2 (de) 2007-06-21
EA007657B1 (ru) 2006-12-29
EP1438049B1 (en) 2006-11-22
HRP20040325A2 (en) 2005-04-30
HK1072562A1 (en) 2005-09-02
US20050004170A1 (en) 2005-01-06
ES2276980T3 (es) 2007-07-01
EP1438049A2 (en) 2004-07-21
KR100967599B1 (ko) 2010-07-05
HUP0402332A2 (hu) 2005-02-28
ZA200402816B (en) 2005-06-29
EA200400547A1 (ru) 2004-10-28
MY139586A (en) 2009-10-30
JP2005507943A (ja) 2005-03-24
MXPA04003480A (es) 2004-07-30
AU2002363369B2 (en) 2008-08-21
ATE345799T1 (de) 2006-12-15
IL161347A0 (en) 2004-09-27
NZ531733A (en) 2006-04-28
US7390822B2 (en) 2008-06-24
DE60216310D1 (de) 2007-01-04
HUP0402332A3 (en) 2009-07-28
UA75980C2 (en) 2006-06-15
WO2003039440A3 (en) 2003-12-18
KR20050035120A (ko) 2005-04-15

Similar Documents

Publication Publication Date Title
NO20041681L (no) Substituerte 4-fenyl-4-[1H-imidazol-2-yl]-piperidinderivater for reduksjon av iskemisk skade
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
NO20045137L (no) Diketohydrazinderivatforbindelser og legemidler inneholdende forbindelser som aktiv ingrediens
WO2001015593A3 (en) Compositions for reducing vascular plaque formation and methods of using same
EP2269610A3 (en) Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP2266569A3 (en) Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
IL173032A0 (en) Pyridazine derivatives and their use as therapeutic agents
NO20062928L (no) Azabenzofuran substituerte tiourear som inhibitorer av viral replikasjon
EP1014996A4 (en) PREPARATION OF SACCHARIDES AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND OTHER AMYLOIDOSES
CA2336909A1 (en) Thiobenzimidazole derivatives which are useful as inhibitors of human chymase activity
BRPI0515483A (pt) derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
NO20053644L (no) (2S)-2-[(4S)-4-(2,2-difluorvinyl)-2-oksopyrrolidinyl ]butanamid og farmasoytisk preparat
MXPA05008172A (es) Derivados de malonamida como inhibidores gamma-secretasa.
MXPA04000328A (es) Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer.
ATE541854T1 (de) Pyrazolderivat, arzneimittelzusammensetzung, die dieses enthält, und zwischenprodukt für dessen herstellung
EP0444196A4 (en) Agent for treatment and prophylaxis of ischemic disease of heart or brain
DE60135108D1 (de) Dermale zusammenstellungen die als wirkstoff coenzym q enthalten
DK1392329T3 (da) Anvendelse af sulodexid til behandling af inflammatorisk tarmsygdom
DE602004007268D1 (de) CYCLOALKYLSULFANYL-SUBSTITUIERTE BENZOiBöTHIOPHENE ALS THERAPEUTISCHE MITTEL
MY147347A (en) Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
BR0210392A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
NO20050573L (no) 4-'7-halo-2-quino (XA) linyloksy ! fenoksypropionsyrederivater som antineoplastiske midler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application